Skip to main content

Advertisement

Table 1 Characteristics of 5 randomized trials comparing gemcitabine to gemcitabine plus platinum analog

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year n Treatment regimen Stage IV (%) Male (%) PS 0–1 (%)
Louvet 2005 156 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 70 53 82
   157 Gem 1000 mg/m2/100 min d1 (FDR) + Oxaliplatin 100 mg/m2 d2 q 2 wks 68 60 83
Poplin 2006 279 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks (standard) 88 56 88
   277 Gem 1500 mg/m2/150 min q wk × 3 of 4 wks (FDR)   58  
   276 Gem 1000 mg/m2/100 min d1 (FDR) + Oxaliplatin 100 mg/m2 d2 q 2 wks   46  
Heinemann 2006 97 Gem 1000 mg/m2 for 3 of 4 wks 79 62 49*
   98 Gem 1000 mg/m2 + Cisplatin 50 mg/m2 q 2 wks 80 65 56*
Colucci 2002 54 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 54 50 med. KPS 70
   53 Gem 1000 mg/m2 + Cisplatin 25 mg/m2 for 6/7 wks 62 66 med. KPS 70
Viret 2004 41 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 78 na 83
   42 Gem 1000 mg/m2 d1, 8, 15 + Cisplatin 75 mg/m2 d15 q 4 wks 81 na 76
  1. * KPS = 90–100%; PS = performance status; FDR = fixed dose rate; na = data not available;